Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04606862
Other study ID # MMSEP1901
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 31, 2020
Est. completion date December 31, 2020

Study information

Verified date October 2020
Source Morley Medical
Contact Kiki Diorgu, MD, MBA
Phone 4048911750
Email adiorgu@morleymed.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a pivotal medical device clinical trial evaluating the clinical outcomes in hospitalized patients monitored with the Morley Medical Sepsis Software Device. The device uses unique AI machine learning algorithms to analyze patient data in real time and generate clinical decision support sepsis risk predictions for clinicians.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 10000
Est. completion date December 31, 2020
Est. primary completion date December 31, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or female patient 18 years of age or older - Patient is admitted or had been admitted to a participating healthcare facility Exclusion Criteria: - Sepsis diagnosis present on admission - Involvement in a clinical trial of another investigational product with similar purpose

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Morley Medical Sepsis Software Device
The Morley Medical Sepsis (MMS) Software Device is a predictive analytics, stand-alone, cloud-based software system with no hardware components. The software acquires patient data from the electronic medical record, processes the data using unique artificial intelligence (AI) powered algorithms, and generates clinical decision support outputs that aid in the proactive delivery of customized and efficient care for patients. The software output is made available to the end users (trained medical professionals) via an intuitive user interface displayed on desktop computers or mobile communication devices such as laptops, smartphones or tablets.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Morley Medical Morley Research Consortium

Outcome

Type Measure Description Time frame Safety issue
Primary In-hospital sepsis prevalence Up to 8 weeks
Primary In-hospital sepsis related 30-day mortality 30 days
Secondary In-hospital all-cause 30-day mortality 30 days
Secondary Hospital length of stay Up to 8 weeks
Secondary Hospital re-admission Up to 8 weeks
Secondary Time of initial IV fluids administration Day 1 to Day 30, or until discharge
Secondary Time of initial vasopressors administration Day 1 to Day 30, or until discharge
Secondary Time of initial antibiotics administration Day 1 to Day 30, or until discharge
Secondary Time of initial blood microbiology culture Day 1 to Day 30, or until discharge
Secondary Sepsis related adverse outcomes (septic shock) Day 1 to Day 30, or until discharge
Secondary Sepsis prediction to onset time Day 1 to Day 30, or until discharge
Secondary Sensitivity and specificity of sepsis prediction Day 1 to Day 30, or until discharge
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3